Weight gain with thiazolidinediones

Medications associated with weight gain include insulin, sulfonylureas, and thiazolidinediones for diabetes, some antidepressants, antipsychotics, and several anticonvulsants. 

Another frequent side effect of insuhn therapy is weight gain. Some is due to increased caloric storage of glucose by insuhn, and some is due to renal sodium retention resulting in fluid retention and edema. These effects can synergize with oral agents that are often coadministered with insuhn, particularly sulfonylureas and thiazolidinediones. 

The thiazolidinediones increase body weight. With trogli-tazone the increase in body weight is accompanied by changed fat distribution, but central fat, in part responsible for the cardiovascular changes seen in diabetes, remains the same weight gain is accompanied by increased subcutaneous fat (72). 

Thiazolidinediones cause recruitment and conversion of pre-adipocytes into adipocytes and are therefore adi-pogenic (75). In 18 patients without diabetes, mean age 46 years, who took pioglitazone 30 mg/day for 48 weeks for non-alcoholic steatohepatitis, there was a mean weight gain of 3.5 kg in 72% (76). Similarly, in 91 patients with type 2 diabetes who took pioglitazone 30 or 45 mg/day for... 

---